Latest Quarter
2026-03-31
Liminatus Pharma Inc Class A Common Stock (LIMN)
Revenue
$0.0
Net Income
-$1.1M
Operating Margin
N/A
Free Cash Flow
-$3.1M
Debt / Assets
661.0%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-03-31 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 518 |
| Gross Profit | -518 |
| Operating Expenses | |
| R&D Expenses | 0 |
| SG&A Expenses | 700,898 |
| Operating Expenses | 1,100,898 |
| Operating Income | -1,100,898 |
| Interest Expense | 18,638 |
| Income Before Tax | -1,123,714 |
| Income Tax Expense | 0 |
| Net Income | -1,123,714 |
| Per Share | |
| EPS | -0.05 |
| EPS Diluted | 0.00 |
| Income Statement (Annual) | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Expenses | ||
| R&D Expenses | 0 | 0 |
| SG&A Expenses | 2,967,812 | 0 |
| Operating Expenses | 2,967,812 | 0 |
| Operating Income | -2,967,812 | -405 |
| Interest Expense | 215,903 | 0 |
| Income Before Tax | -10,206,517 | -405 |
| Income Tax Expense | 0 | 0 |
| Net Income | -10,206,517 | -405 |
| Per Share | ||
| EPS | -0.43 | -4.05 |
| EPS Diluted | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2024-12-31 |
|---|---|
| Assets | |
| Cash and Cash Equivalents | 804,538 |
| Short Term Investments | 0 |
| Net Receivables | 6,456 |
| Inventory | 0 |
| Total Current Assets | 812,658 |
| Property Plant Equipment | 0 |
| Goodwill and Intangibles | 0 |
| Total Assets | 2,828,932 |
| Liabilities | |
| Account Payables | 0 |
| Short Term Debt | 5,122,220 |
| Total Current Liabilities | 8,681,431 |
| Long Term Debt | 0 |
| Total Liabilities | 18,698,831 |
| Shareholders Equity | |
| Retained Earnings | -17,518,175 |
| Total Shareholders Equity | -15,869,899 |
| Balance Sheet (Annual) | 2024-12-31 |
|---|---|
| Assets | |
| Cash and Cash Equivalents | 804,538 |
| Short Term Investments | 0 |
| Net Receivables | 6,456 |
| Inventory | 0 |
| Total Current Assets | 812,658 |
| Property Plant Equipment | 0 |
| Goodwill and Intangibles | 0 |
| Total Assets | 2,828,932 |
| Liabilities | |
| Account Payables | 0 |
| Short Term Debt | 5,122,220 |
| Total Current Liabilities | 8,681,431 |
| Long Term Debt | 0 |
| Total Liabilities | 18,698,831 |
| Shareholders Equity | |
| Retained Earnings | -17,518,175 |
| Total Shareholders Equity | -15,869,899 |
| Cash Flow Statement (Quarterly) | 2024-12-31 |
|---|---|
| Operating Activities | |
| Net Income | -2,904,299 |
| Depreciation & Amortization | 0 |
| Stock Based Compensation | 0 |
| Change in Working Capital | -44,539 |
| Operating Cash Flow | -3,106,462 |
| Investing Activities | |
| Capital Expenditure | 0 |
| Investments | 0 |
| Investing Cash Flow | 1,968,249 |
| Financing Activities | |
| Debt Repayment | 2,850,000 |
| Common Stock Issued/Repurchased | -1,802,869 |
| Dividends Paid | 0 |
| Financing Cash Flow | 1,047,131 |
| Summary | |
| Free Cash Flow | -3,106,460 |
| Net Change in Cash | 648,113 |
| Cash Flow Statement (Annual) | 2024-12-31 |
|---|---|
| Operating Activities | |
| Net Income | -2,904,299 |
| Depreciation & Amortization | 0 |
| Stock Based Compensation | 0 |
| Change in Working Capital | -44,539 |
| Operating Cash Flow | -3,106,462 |
| Investing Activities | |
| Capital Expenditure | 0 |
| Investments | 0 |
| Investing Cash Flow | 1,968,249 |
| Financing Activities | |
| Debt Repayment | 2,850,000 |
| Common Stock Issued/Repurchased | -1,802,869 |
| Dividends Paid | 0 |
| Financing Cash Flow | 1,047,131 |
| Summary | |
| Free Cash Flow | -3,106,460 |
| Net Change in Cash | 648,113 |